Vision Monday


Dr. Brian Marr Named Director of Ophthalmic Oncology at NewYork-Presbyterian/Columbia Medical Center

By Staff
Wednesday, May 24, 2017 12:15 AM

Dr. Brian Marr.

NEW YORK—Dr. Brian Marr will join the department of ophthalmology at NewYork-Presbyterian/Columbia University Medical Center as director of the division of ophthalmic oncology, effective May 15. He will also serve as a professor of ophthalmology at Columbia University Medical Center, according to an announcement from the Medical Center.

With Dr. Marr’s arrival, the Medical Center is establishing one of the largest and most comprehensive ocular melanoma programs in the country, the announcement said. Dr. Marr will be working alongside medical oncologists, in keeping with NewYork-Presbyterian/Columbia University Medical Center’s team-based approach to cancer care. Prior to joining NewYork-Presbyterian/Columbia, he worked at Memorial Sloan-Kettering Cancer Center.

“Dr. Marr is a renowned leader in the diagnosis, treatment and management of eye cancers, and we are pleased to welcome him to NewYork-Presbyterian/Columbia University Medical Center,” said Dr. George A. “Jack” Cioffi, the Edward S. Harkness chairman of the Department of Ophthalmology and ophthalmologist-in-chief at New York-Presbyterian/Columbia University Medical Center.

As one of the few ocular oncologists trained in all aspects of eye cancers, Dr. Marr’s clinical experience in treating these diseases is among the most extensive in the world. He has devised and performed thousands of surgical procedures on tumors of the eye, eyelid, orbit and conjunctiva in adults, children and infants, and is one of the few surgeons experienced in intraocular tumor resection, as well as advanced laser, radiation and chemotherapy treatments.

A board-certified ophthalmologist, Dr. Marr is a member of the American Medical Association and a board-certified fellow of the American Academy of Ophthalmology, for which he has lectured frequently. He was recognized as one of New York Magazine’s “Top Doctors” from 2014 to 2016.
Also Recommended
Johnson & Johnson Vision Announces FDA Approval of iDESIGN Refractive Studio
ICO and Allergan Announce Advanced Research Fellowship Winner
Essilor Sets Notice for First General Meeting of EssilorLuxottica—Once Deal Closes
The McGee Group Launches New Division, the Reading Glass Company
Home VM Mobile